SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:lup.lub.lu.se:1206a378-ad60-4ce6-bbe7-cc6bff1c59d7"
 

Search: onr:"swepub:oai:lup.lub.lu.se:1206a378-ad60-4ce6-bbe7-cc6bff1c59d7" > Ewing Sarcoma: Curr...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Gaspar, Nathalie (author)

Ewing Sarcoma: Current Management and Future Approaches Through Collaboration.

  • Article/chapterEnglish2015

Publisher, publication year, extent ...

  • 2015

Numbers

  • LIBRIS-ID:oai:lup.lub.lu.se:1206a378-ad60-4ce6-bbe7-cc6bff1c59d7
  • https://lup.lub.lu.se/record/7834810URI
  • https://doi.org/10.1200/JCO.2014.59.5256DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:for swepub-publicationtype
  • Subject category:ref swepub-contenttype

Notes

  • Ewing sarcoma (ES) is an aggressive sarcoma of bone and soft tissue occurring at any age with a peak incidence in adolescents and young adults. The treatment of ES relies on a multidisciplinary approach, coupling risk-adapted intensive neoadjuvant and adjuvant chemotherapies with surgery and/or radiotherapy for control of the primary site and possible metastatic disease. The optimization of ES multimodality therapeutic strategies has resulted from the efforts of several national and international groups in Europe and North America and from cooperation between pediatric and medical oncologists. Successive first-line trials addressed the efficacy of various cyclic combinations of drugs incorporating doxorubicin, vincristine, cyclophosphamide, ifosfamide, etoposide, and dactinomycin and identified prognostic factors now used to tailor therapies. The role of high-dose chemotherapy is still debated. Current 5-year overall survival for patients with localized disease is 65% to 75%. Patients with metastases have a 5-year overall survival < 30%, except for those with isolated pulmonary metastasis (approximately 50%). Patients with recurrence have a dismal prognosis. The many insights into the biology of the EWS-FLI1 protein in the initiation and progression of ES remain to be translated into novel therapeutic strategies. Current options and future approaches will be discussed.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Hawkins, Douglas S (author)
  • Dirksen, Uta (author)
  • Lewis, Ian J (author)
  • Ferrari, Stefano (author)
  • Le Deley, Marie-Cecile (author)
  • Kovar, Heinrich (author)
  • Grimer, Robert (author)
  • Whelan, Jeremy (author)
  • Claude, Line (author)
  • Delattre, Olivier (author)
  • Paulussen, Michael (author)
  • Picci, Piero (author)
  • Sundby Hall, Kirsten (author)
  • van den Berg, Hendrik (author)
  • Ladenstein, Ruth (author)
  • Michon, Jean (author)
  • Hjorth, LarsLund University,Lunds universitet,Pediatrik, Lund,Sektion V,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Paediatrics (Lund),Section V,Department of Clinical Sciences, Lund,Faculty of Medicine(Swepub:lu)pedi-lhj (author)
  • Judson, Ian (author)
  • Luksch, Roberto (author)
  • Bernstein, Mark L (author)
  • Marec-Bérard, Perrine (author)
  • Brennan, Bernadette (author)
  • Craft, Alan W (author)
  • Womer, Richard B (author)
  • Juergens, Heribert (author)
  • Oberlin, Odile (author)
  • Pediatrik, LundSektion V (creator_code:org_t)

Related titles

  • In:Journal of Clinical Oncology33:27, s. 140-30361527-7755

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view